PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed (Faculty Presentations)PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed (Faculty Presentations)
Johann S de Bono, MB ChB, MSc, PhD, FMedSci
Regius Professor of Cancer Research Professor of Experimental Cancer Medicine and Honorary Consultant in Medical Oncology Head of Clinical Studies Division Director of Drug Development Unit Head of the Prostate Cancer Targeted Therapy Group The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust London, United Kingdom Fred Saad, MD |